Peps
What is Thymopentin?
Thymopentin is a synthetic pentapeptide studied as an immunomodulator. A small 1985 randomized trial examined active rheumatoid arthritis.
Biological role or research focus
Historical immune-disease research.
The trial was small, short, and historical. It does not establish sustained disease control, prevention of structural joint damage, or benefit across unrelated immune conditions.
Role reference: Confirmative study of the effectiveness of thymopentin in active rheumatoid arthritis. · 1985 ↗
Names you may encounter
TP-5
Search terms can include brands, combinations, or historical names. They are not automatic product equivalents.
- Class / identity
- Synthetic five-residue immunomodulatory peptide
- Research focus
- Historical immune-disease research
- Featured evidence
- Human randomized trial
- Source check
- October 4, 2026
Source: Confirmative study of the effectiveness of thymopentin in active rheumatoid arthritis. · 1985 ↗
Molecular structure
How Thymopentin works
Its research concerns modification of immune responses. The selected trial measured clinical and immunological outcomes, which should be distinguished rather than described as a general “immune boost.”
Source: Confirmative study of the effectiveness of thymopentin in active rheumatoid arthritis. · 1985 ↗
Clinical context & research status
This historical study does not establish thymopentin as a current standard of rheumatoid-arthritis care, or as general infection prevention.
Source: Confirmative study of the effectiveness of thymopentin in active rheumatoid arthritis. · 1985 ↗
What does the evidence show?
Selected published evidence, with the population, findings, and limits kept together. These original summaries draw on publication abstracts; they are not a systematic review.
Human randomized trial · 1985
Thymopentin rheumatoid-arthritis study
Did clinical and immunological rheumatoid-arthritis measures change?
- Population / model
- 41 patients with active rheumatoid arthritis; 21 received thymopentin and 20 received placebo.
- Study design
- Randomized double-blind placebo-controlled study over three weeks.
- Main finding
- Some joint, pain, and Ritchie-index measures improved between groups. The reported immunological tests did not show corresponding improvements.
- Limits & context
- The trial was small, short, and historical. It does not establish sustained disease control, prevention of structural joint damage, or benefit across unrelated immune conditions.
Source: Confirmative study of the effectiveness of thymopentin in active rheumatoid arthritis. · 1985 ↗
Read the original paper for methods, adverse events, funding, and conflicts of interest. Publisher access may require a subscription.
Further reading · 4 additional publication links
Exact-name PubMed search checked 2026-10-04. These records have not been appraised. A name match can include related compounds, combinations, or other formulations; it does not establish safety or benefit.
Copper-coordination driven brain-targeting nanoassembly for efficient glioblastoma multiforme immunotherapy by cuproptosis-mediated tumor immune microenvironment reprogramming. ↗
Journal of nanobiotechnology · 2024 Dec 28 · Journal Article
Read available full text ↗
Thymopentin: safety overview. ↗
Survey of immunologic research · 1985 · Clinical Trial, Journal Article
Thymopentin in dermatology. ↗
Current problems in dermatology · 1989 · Journal Article, Review
Thymopoietin to thymopentin: experimental studies. ↗
Survey of immunologic research · 1985 · Journal Article, Review
New editorial updates
New source discoveries
Links appear automatically. Unreviewed discoveries are not verified medical findings.
Safety & precautions
What the featured evidence can tell us
Three weeks of observation in 41 patients cannot resolve long-term immune effects, interactions, or uncommon adverse reactions.
Source: Confirmative study of the effectiveness of thymopentin in active rheumatoid arthritis. · 1985 ↗
Identity, route, and evidence limits
The trial was small, short, and historical. It does not establish sustained disease control, prevention of structural joint damage, or benefit across unrelated immune conditions.
Source: Confirmative study of the effectiveness of thymopentin in active rheumatoid arthritis. · 1985 ↗
This is not a complete list of contraindications, interactions, or adverse effects. Medicine labels apply to specific products and indications; research-use listings are not interchangeable with approved medicines.
What are people discussing?
No editorial transcript note has been reviewed for this profile yet. Below are the matching video records available for exploration; title and caption matches are not verified claims.
Watch the source discussions
0 matching video records · 0 with captions indexed.
Across the full library, 30 caption files are indexed from 20,199 inventoried videos. Most transcripts remain unreviewed. Select a thumbnail or timestamp to watch inside PepsRadar. Thumbnail images load from YouTube.
No matching video has been identified in the current snapshot.
Sources & supplier listings
Listings are grouped by the vendor’s stated identity. Blends and modified derivatives are labeled separately. Inclusion is not a quality assessment or an endorsement.
We have not added a supplier for this profile. Missing products and coded listings are not filled with guesses.
Catalog checked 2026-10-04. Seller listings retain their stated intended use. Shops covered: BioLongevity Labs, BioLongevity Supplements, American Peptides, PSPeptides. This is not a market-wide comparison. Affiliate participation does not determine evidence or editorial coverage.
Questions worth asking
- Is immunomodulation the same as stronger immunity?
- What population, comparator, and route were actually studied?
- The trial was small, short, and historical. It does not establish sustained disease control, prevention of structural joint damage, or benefit across unrelated immune conditions.
- What adverse effects, uncertainty, and conflicts of interest does the original source report?
Frequently asked questions
Is immunomodulation the same as stronger immunity?
No. Immune signaling is context dependent. Improvement in a particular symptom study cannot establish general resistance to infections.
Source: Confirmative study of the effectiveness of thymopentin in active rheumatoid arthritis. · 1985 ↗
Does this page establish a supplier’s product quality?
No. A publication describes its own tested material. It does not verify a supplier listing, batch identity, purity, or clinical suitability.
Source: Confirmative study of the effectiveness of thymopentin in active rheumatoid arthritis. · 1985 ↗
References & editorial record
Source notes checked 2026-10-04. Original PepsRadar summaries. Not reviewed by a medical professional. Topic grouping is editorial navigation, not a treatment recommendation. Video notes specify which excerpts were reviewed; no full transcripts are published.